MorphoSys AG (ETR:MOR) Given Consensus Recommendation of “Hold” by Analysts

Share on StockTwits

MorphoSys AG (ETR:MOR) has received a consensus recommendation of “Hold” from the seven analysts that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is €119.86 ($139.37).

Several research firms recently weighed in on MOR. Royal Bank of Canada set a €130.00 ($151.16) price objective on shares of MorphoSys and gave the stock a “buy” rating in a research report on Tuesday, November 19th. HSBC set a €81.00 ($94.19) target price on shares of MorphoSys and gave the company a “sell” rating in a research report on Friday, August 16th. Goldman Sachs Group set a €114.00 ($132.56) price target on shares of MorphoSys and gave the stock a “neutral” rating in a research note on Tuesday, November 19th. Independent Research set a €110.00 ($127.91) price target on shares of MorphoSys and gave the stock a “neutral” rating in a report on Friday, November 1st. Finally, Berenberg Bank set a €145.00 ($168.60) price target on shares of MorphoSys and gave the stock a “buy” rating in a report on Wednesday, December 4th.

Shares of MOR opened at €120.40 ($140.00) on Monday. MorphoSys has a 12-month low of €79.70 ($92.67) and a 12-month high of €118.90 ($138.26). The company has a current ratio of 7.80, a quick ratio of 7.63 and a debt-to-equity ratio of 9.78. The company has a market cap of $3.80 billion and a PE ratio of -39.58. The stock has a 50-day moving average price of €102.88 and a 200-day moving average price of €99.16.

About MorphoSys

MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.

Recommended Story: Back-End Load

Analyst Recommendations for MorphoSys (ETR:MOR)

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.